New drug MHB018A aims to reduce eye bulging in thyroid eye disease
NCT ID NCT07622121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an injection called MHB018A for people with chronic moderate-to-severe thyroid eye disease. About 135 participants will receive either the drug or a placebo every 4 weeks for 24 weeks. The main goal is to see if the drug reduces eye bulging by at least 2 millimeters without worsening the other eye.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MHB018A injection
- What this could lead to
- If it works, this could provide a new treatment option to reduce eye bulging and inflammation in people with chronic thyroid eye disease.
- What could go wrong
- This is a Phase 3 trial, but results may not show significant benefit over placebo. The condition is chronic, and treatment may not eliminate the need for other therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MODERATE-TO-SEVERE THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill reverse eye bulging in thyroid eye disease?
- Could your Phone's camera help track thyroid eye disease?
- New drug aims to ease bulging eyes in thyroid disease patients
- New shot aims to reduce bulging eyes from thyroid disease
- New pill could help when steroids fail for bulging eyes
- New drug cizutamig enters early trial for thyroid eye disease